In after-hours trade Tuesday, Supernus Pharmaceuticals (SUPN) shares soared more than 24% percent to $27.99, following the firm revealed promising findings from a trial of its new treatment for attention deficit hyperactivity disorder, or ADHD. Supernus reported Tuesday afternoon that its intended goal was met in a phase 3 trial of the medication, known as SPN-812, in adults.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
The Food and Drug Administration is actively reviewing the drug for use in children aged 6 to 17, and once it is approved by the FDA, Supernus plans to ask that the drug be considered for adults as well.
Shares surged more than 40% as trades resumed after the end of after-hours trading Tuesday afternoon, but gradually declined to around 20 percentsurge by the end of the extended session.
Read More
